LARETH-25 and β-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  International journal of pharmaceutics

• Publication date

  2016-12-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijpharm.2016.09.054PMID 27720872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical determination of the site of antidepressant-like effects of glucagon-like peptide-2 in ACTH-treated mice.

  2015cited by this paper
• Solid state characterization of α-tocopherol in inclusion complexes with cyclodextrins.

  2015cited by this paper
• Glucagon-like peptide-2 but not imipramine exhibits antidepressant-like effects in ACTH-treated mice.

  2013cited by this paper
• Characterization of the hypotensive effects of glucagon-like peptide-2 in anesthetized rats.

  2013cited by this paper
• Immunohistochemical determination of the site of hypotensive effects of glucagon-like peptide-2 in the rat brain.

  2012cited by this paper
• [Basic studies on the nasal delivery of insulin].

  2012cited by this paper
• Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways.

  2009cited by this paper
• Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies.

  2007cited by this paper
• [Strategy to develop a new drug for treatment-resistant depression--role of electroconvulsive stimuli and BDNF].

  2007cited by this paper
• [Claudin as a novel target for drug delivery system].

  2006cited by this paper
• Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells.

  2004cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

  2004cited by this paper
• Modulation of specific intestinal epithelial progenitors by enteric neurons

  2001cited by this paper
• Glucagon-like peptide containing pathways in the regulation of feeding behaviour

  2001cited by this paper
• The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake

  2000cited by this paper
• Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.

  2000cited by this paper
• In vivo and in vitro degradation of glucagon-like peptide-2 in humans.

  2000cited by this paper
• Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

  1999cited by this paper
• Role of prohormone convertases in the tissue-specific processing of proglucagon.

  1996cited by this paper
• Proline residues in the maturation and degradation of peptide hormones and neuropeptides

  1988cited by this paper
• Post-proline dipeptidyl-aminopeptidase from synaptosomal membranes of guinea-pig brain. A possible role for this activity in the hydrolysis of His-ProNH2, arising from the action of synaptosomal membrane pyroglutamate aminopeptidase on thyroliberin.

  1986cited by this paper
• Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

  1986cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper

• Advancing Antidepressive Agents: Drug Discovery and Polymer-Based Drug Delivery Systems for Improved Treatment Outcome

  2025cites this paper
• [Development of Drug Delivery Systems Based on New Concepts].

  2025cites this paper
• The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases

  2025cites this paper
• GLP-1 derivatives with functional sequences transit and migrate through trigeminal neurons.

  2024cites this paper
• Intranasal administration nanosystems for brain-targeted drug delivery

  2023cites this paper
• A Comprehensive Review of Advanced Nasal Delivery: Specially Insulin and Calcitonin.

  2023cites this paper
• Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative.

  2022cites this paper
• The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review

  2022cites this paper
• Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients

  2022cites this paper
• Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?

  2021cites this paper
• Active targeting towards and inside the brain based on nanoparticles: A Review.

  2019cites this paper
• [Improving Effects of Peptides on Brain Malfunction and Intranasal Delivery of Those Derivatives to the Brain].

  2019cites this paper
• Cyclodextrins improving the physicochemical and pharmacological properties of antidepressant drugs: a patent review

  2018cites this paper